Salarius Pharmaceuticals, Inc. SLRX · Stock Open Salarius Pharmaceuticals, Inc. in new tab
Salarius Pharmaceuticals, Inc. Analysis (SLRX)
Is Salarius Pharmaceuticals, Inc. a good investment? Salarius Pharmaceuticals, Inc. (SLRX) is currently trading at 0.8400 USD.
Earnings Schedule: Salarius Pharmaceuticals, Inc. is expected to release its next earnings report on May 12, 2026. The market consensus estimate for Forward EPS is -9.17.
Investor FAQ
Does Salarius Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Salarius Pharmaceuticals, Inc.?
Salarius Pharmaceuticals, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be May 12, 2026. The company currently has a trailing EPS of -24.24.
Company Profile
Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. Salarius Pharmaceuticals, Inc. is based in Houston, Texas.
| Split Date | Split Ratio to 1 |
|---|---|
| July 22, 2019 | 1:25 |
| Oct. 17, 2022 | 1:25 |
| June 17, 2024 | Needs review |
| Aug. 18, 2025 | 0.07 |
Community Discussion